Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain
Background: Impetigo is a common dermatological paediatric infection that can be treated with topical antibiotics: the common are mupirocin (MUP), fusidic acid (FA) and, most recently, ozenoxacin (OZ). Aim: This study assesses the clinical and economic consequences of the use of OZ vs. MUP and vs....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2022-10-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2439 |
| _version_ | 1811237583900901376 |
|---|---|
| author | Jaime Rodríguez Quintosa Cintia Cristina Ago Antoni Sicras Mainar Renata Villoro Inés Pérez-Román |
| author_facet | Jaime Rodríguez Quintosa Cintia Cristina Ago Antoni Sicras Mainar Renata Villoro Inés Pérez-Román |
| author_sort | Jaime Rodríguez Quintosa |
| collection | DOAJ |
| description | Background: Impetigo is a common dermatological paediatric infection that can be treated with topical antibiotics: the common are mupirocin (MUP), fusidic acid (FA) and, most recently, ozenoxacin (OZ).
Aim: This study assesses the clinical and economic consequences of the use of OZ vs. MUP and vs. FA for the treatment of impetigo in routine clinical practice in Spain.
Methods: This is a retrospective observational study using real-life data from electronic medical records of patients with impetigo who started treatment with OZ, MUP or FA (maximum follow-up: 3 months; n = 10,974). We compared treatment duration, comorbidities, use of systemic medication, complications, utilization of resources and associated costs across treatments (p<0.05). Cost-effectiveness of OZ was assessed from a social perspective. Complication rates and treatment duration were the effectiveness measures.
Results: Mean age was 12.6 (standard deviation [SD]: 16.6) years; 48.6% were male; treatment: 9.3% (OZ), 56.4% (MUP), 34.5% (FA). The percentage of patients ending treatment after 2 weeks was 87.6% (OZ) vs. 83.2% (MUP) vs. 82.4% (FA); p<0.001; complication rates were 1.8% (OZ), 3.3% (MUP) and 3.2% (FA), p<0.001; mean costs were €158 (OZ), €265 (MUP) and €287 (FA), p<0.001.
Conclusions: OZ is a cost-effective and dominant alternative for the treatment of impetigo.
|
| first_indexed | 2024-04-12T12:26:29Z |
| format | Article |
| id | doaj.art-95958a75673c488f94ae2a01b65864c7 |
| institution | Directory Open Access Journal |
| issn | 2284-2403 2283-5733 |
| language | English |
| last_indexed | 2024-04-12T12:26:29Z |
| publishDate | 2022-10-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj.art-95958a75673c488f94ae2a01b65864c72022-12-22T03:33:09ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332022-10-019110.33393/grhta.2022.2439Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in SpainJaime Rodríguez Quintosa0Cintia Cristina Ago1Antoni Sicras Mainar2Renata Villoro3Inés Pérez-Román4Primary Care Center of Olesa de Montserrat, Catalonia - SpainHospital Comarcal del Alt Penedés Garraf, Catalonia - SpainHealth Economics and Outcomes Research Department, Atrys Health, Madrid - SpainHealth Economics and Outcomes Research Department, Atrys Health, Madrid - SpainHealth Economics and Outcomes Research Department, Atrys Health, Madrid - SpainBackground: Impetigo is a common dermatological paediatric infection that can be treated with topical antibiotics: the common are mupirocin (MUP), fusidic acid (FA) and, most recently, ozenoxacin (OZ). Aim: This study assesses the clinical and economic consequences of the use of OZ vs. MUP and vs. FA for the treatment of impetigo in routine clinical practice in Spain. Methods: This is a retrospective observational study using real-life data from electronic medical records of patients with impetigo who started treatment with OZ, MUP or FA (maximum follow-up: 3 months; n = 10,974). We compared treatment duration, comorbidities, use of systemic medication, complications, utilization of resources and associated costs across treatments (p<0.05). Cost-effectiveness of OZ was assessed from a social perspective. Complication rates and treatment duration were the effectiveness measures. Results: Mean age was 12.6 (standard deviation [SD]: 16.6) years; 48.6% were male; treatment: 9.3% (OZ), 56.4% (MUP), 34.5% (FA). The percentage of patients ending treatment after 2 weeks was 87.6% (OZ) vs. 83.2% (MUP) vs. 82.4% (FA); p<0.001; complication rates were 1.8% (OZ), 3.3% (MUP) and 3.2% (FA), p<0.001; mean costs were €158 (OZ), €265 (MUP) and €287 (FA), p<0.001. Conclusions: OZ is a cost-effective and dominant alternative for the treatment of impetigo. https://journals.aboutscience.eu/index.php/grhta/article/view/2439Cost-effectivenessImpetigoOzenoxacin |
| spellingShingle | Jaime Rodríguez Quintosa Cintia Cristina Ago Antoni Sicras Mainar Renata Villoro Inés Pérez-Román Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain Global & Regional Health Technology Assessment Cost-effectiveness Impetigo Ozenoxacin |
| title | Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain |
| title_full | Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain |
| title_fullStr | Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain |
| title_full_unstemmed | Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain |
| title_short | Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain |
| title_sort | clinical and economic consequences of ozenoxacin vs other topical antibiotics for the treatment of impetigo a real life study in spain |
| topic | Cost-effectiveness Impetigo Ozenoxacin |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/2439 |
| work_keys_str_mv | AT jaimerodriguezquintosa clinicalandeconomicconsequencesofozenoxacinvsothertopicalantibioticsforthetreatmentofimpetigoareallifestudyinspain AT cintiacristinaago clinicalandeconomicconsequencesofozenoxacinvsothertopicalantibioticsforthetreatmentofimpetigoareallifestudyinspain AT antonisicrasmainar clinicalandeconomicconsequencesofozenoxacinvsothertopicalantibioticsforthetreatmentofimpetigoareallifestudyinspain AT renatavilloro clinicalandeconomicconsequencesofozenoxacinvsothertopicalantibioticsforthetreatmentofimpetigoareallifestudyinspain AT inesperezroman clinicalandeconomicconsequencesofozenoxacinvsothertopicalantibioticsforthetreatmentofimpetigoareallifestudyinspain |